The FDA has approved the first blood test for Alzheimer's disease based on a blood test – from Fujirebio – in a step forward ...

The pharmaceutical landscape in 2024 was undeniably shaped by the remarkable rise of GLP-1 receptor agonists. Once primarily recognised for their role in managing type 2 diabetes, these therapies ...

Informed consent is a foundational element of every clinical trial. Yet, the traditional paper-based process has long been associated with delays, documentation errors, and disengaged participants.

These have been dark days for the global economy, and the short-term prospects for the pharmaceutical industry look uncertain. The industry is currently undergoing change and restructuring on an ...

At the recent AAPS National Biotech Conference 2025, pharmaphorum editor-in-chief Jonah Comstock caught up with Dr Dhaval Shah, a professor of pharmaceutical sciences at the University of Buffalo and ...

Jørgensen has agreed to stay on while the search for a successor is carried out, and the chair of the Novo Nordisk Foundation ...

The latecomer PD-1 inhibitor – already approved for Merkel cell carcinoma – has become the first cancer immunotherapy for ...

Health tech firm Datavant has reached an agreement to acquire Aetion, a specialist in real-world evidence (RWE), pooling ...

The infant was born with a metabolic disorder called severe carbamoyl phosphate synthetase 1 (CPS1) deficiency, in which the ...

Following after is P-500, a selective, brain-penetrant PRMT5 inhibitor for advanced solid tumours, including high-grade ...

Changes to Health Technology Assessment (HTA) in Europe offer new opportunities to streamline processes and get innovative ...

The CAR-T landscape has quickly transformed from a pioneering breakthrough to a highly competitive and evolving market. Ben Hargreaves finds that the early leaders, Gilead and Novartis, are now ...